MONEY20/20
16.4.2024 09:01:32 CEST | Business Wire | Press release
Money20/20, the world’s leading fintech show and the place where money does business, unveils its agenda for its upcoming Europe show in Amsterdam, 4-6 June. 350+ speakers are expected to take the stage in Amsterdam this year including C-suite executives from global banks such as Deutsche Bank and ING; fintech players such as Adyen and Revolut, senior representatives from the European Central Bank and the European Commission, and blockchain solution providers such as Ripple. The show promises an amalgamation of expertise, from the Wirecard whistleblower Pav Gill to tech evangelist Prince Constantijn van Oranje-Nassau of the Netherlands.
Under the theme of ‘Human X Machine’, Money20/20 Europe 2024 will explore the dynamic relationship between humans and intelligent machines, focusing on how the partnership between artificial and human intelligence will forge a new era in finance. In line with this, Money20/20 Europe also welcomes the CEOs of AI firms including Mistral AI, Datasnipper and Deeploy, alongside executives from the world of cryptocurrency including Kraken and Fireblocks. Nvidia and AWS are back again co-hosting a summit with Money20/20 deep diving into AI.
Scarlett Sieber, Money20/20's Chief Strategy & Growth Officer, emphasised the significance of this year's theme, saying, "I’m delighted to welcome such esteemed powerhouses in the world of finance to what promises to be our biggest and most impactful show in Europe yet. As I will discuss with Former French President François Hollande in our fireside chat, Human X Machine encapsulates the essence of our rapidly evolving financial landscape and underscores the critical intersection of human ingenuity and artificial intelligence in shaping our financial future. The power of the Money20/20 platform is that the collective ecosystem of money at the most senior level comes together to have active discussions on the most important topics, breaking news, and work together to pave the way for a more resilient and inclusive financial ecosystem.”
Pav Gill, the Wirecard whistleblower, and one of Money20/20 Europe’s keynote speakers said, "Speaking at Money20/20 Europe is more than an opportunity; it's a reflection of a journey that took me from the heart of the Wirecard scandal to the helm of Confide. Unveiling one of finance's largest deceptions wasn't just about exposing truths; it was about sparking change. At Confide, we're building the future of business integrity, using technology to ensure that the lessons learned from Wirecard and the many other scandals pave the way for a more accountable and transparent industry. I look forward to sharing this mission and inspiring action towards a culture where ethics and technology intersect to create safer business environments for all.”
Sessions at Money20/20 Europe will revolve around five key topic areas within the show’s Human X Machine theme. They are as follows:
- A Customer Universe of One: Finance is becoming a Universe of One; A place where hyper-personalisation occurs at a microscopic level across every touchpoint.
- The Age of Atomic Finance: The Universe of One is made possible by monumental technological advancements, from artificial intelligence and cryptography to quantum computing. These leaps in technology have delivered atomic-level precision, unlocking the potential for a Universe of One.
- Meet the Architects: From the leaders of trailblazing startups to changemakers in agile incumbents, we’ll showcase the architects of the new dawn; the visionaries who create new landscapes for our financial futures.
- Signal Vs Noise: The pace of financial innovation continues accelerating, fueled by emerging technologies like AI, blockchain, and Web3. Yet visionary breakthroughs live alongside hype-driven tangents. We need voices committed to elevating discourse and realising technology’s potential through innovation geared towards progress.
- The Business of Money: Hear from founders, key decision makers, consultants, investors, and disruptors. We’ll delve into the actions that led to success, and just as crucially we’ll carry out an audit on the activities that produced undesirable outcomes.
The Money20/20 Europe agenda can be found here, while the lineup of confirmed speakers can be found here.
Media who would like to attend Money20/20 Europe can register for a complimentary press pass here.
About Money20/20
Launched by industry insiders in 2012, Money20/20 has rapidly become the heartbeat of the global fintech ecosystem. Over the last decade, the most innovative, fast-moving ideas and companies have driven their growth on our platform. Mastercard, Airwallex, J.P. Morgan, SHIELD, GCash, Stripe, Google, Marqeta, VISA, Adyen, Checkout.com and more make transformational deals and raise their global profile with us. Money20/20 attracts leaders from the world’s greatest VC firms, banks, regulators and media platforms: convening to cut industry-shaping deals, build world-changing partnerships and unlock future-defining opportunities in Bangkok (23-25 April 2024), Amsterdam (4-6 June 2024) and Las Vegas (27-30 October 2024). Money20/20 also recently launched Twentyfold, a Digital Intelligence product containing the deepest and widest repository of fintech startup data in the world. Money20/20 is where the world’s fintech leaders convene to grow their businesses. Money20/20 is part of Ascential plc. Follow Money20/20 on X and LinkedIn for show developments and updates. We’re Where Money Does Business.
Follow Money20/20 on Twitter for show developments and updates.
You can also find us on LinkedIn at Money20/20.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416620432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom